18F-fluorocholine and 18F-fluoride PET in Prostate Cancer

• Status: Completed
• Trial end date: 2019-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

Prostate cancer remains to be a public health problem around the world. For patients with prostate cancer, diphosphonate bone scintigraphy (BS) and pelvic tomographic imaging are major imaging tools to evaluate the disease spread. However, the conventional image modalities have only limited sensitivity and specificity. New imaging tracer with 18F-fluorocholine (18F-FCH) and old radiopharmaceuticals with NaF has showed promising results in detecting prostate cancers over bone scan. Nevertheless, the diagnostic performance of each tool has less been compared.

The goal of this study is to compare the diagnostic performance of 18F-FCH PET/CT and NaF PET/CT for prostate cancer patients.

The investigators prospectively enroll patients with the pathological diagnosis of prostate cancer and intended to receive radionuclide bone image. The patients will receive NaF PET/CT and 18F-FCH PET/CT. Each image will be evaluated by experienced interpreter for abnormal uptake suspicious for cancer spreading. The reference standard will be a combination of tissue correlation, imaging, laboratory and clinical data. Diagnostic performance of both PET/CT scans will be measured and calculated.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Buddhist Tzu Chi General Hospital
• Treatments: Choline

Criteria

Inclusion Criteria:

• Patients are pathologically diagnosed with prostate adenocarcinoma.

• Received NaF PET/CT.

Exclusion Criteria:

• Diagnosed to have multiple cancers

• Younger than 20-year-old

• Known allergic to investigational drug

• The patients is classified as not suited for the exam by the investigators.